CTOs on the Move

Marinus Pharmaceuticals

www.marinuspharma.com

 
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.marinuspharma.com
  • 5 Radnor Corporate Center 100 Matsonford Road Suite 500
    Radnor, PA USA 19087
  • Phone: 484.801.4670

Executives

Name Title Contact Details

Funding

Marinus Pharmaceuticals raised $70M on 12/13/2019

Similar Companies

Napp Technologies

Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aktiv Pharma Group

Aktiv Pharma Group is a company that develops drug delivery technology for emergency situations, with a focus on the ARAI auto injector for opioid overdose, hypoglycemia, and severe allergies like anaphylaxis.

Boc Sciences

Boc Sciences is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clyde Chemists

Clyde Chemists is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.